Brief: GSK's mRNA flu vaccine moves into Phase III testing
01/09/2026 07:56
BRIEF-GSK's mRNA flu vaccine moves into Phase III testing Sept 1 (Reuters) - GSK plc GSK.L:
GSK PLC - MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III
GSK PLC - MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III
GSK: PHASE III TRIAL TO START IN SEPTEMBER 2026
GSK: PHASE III TRIAL TO START IN SEPTEMBER 2026
GSK: VACCINE CANDIDATE DESIGNED TO TARGET TWO PRIMARY SURFACE ANTIGENS THAT CAUSE FLU VIRUSES TO BIND AND SPREAD
GSK: VACCINE CANDIDATE DESIGNED TO TARGET TWO PRIMARY SURFACE ANTIGENS THAT CAUSE FLU VIRUSES TO BIND AND SPREAD
Source text: ID:nRSA7702Sa
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;;))